A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

NCT02824458 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

246

Enrollment

OTHER

Sponsor class

Conditions

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

Interventions

DRUG: Apatinib
DRUG: Gefitinib
DRUG: Placebo

Sponsor

Sun Yat-sen University